A phase I trial of APX 3330 for the treatment of pancreatic cancer
Phase of Trial: Phase I
Latest Information Update: 01 Mar 2017
At a glance
- Drugs APX 3330 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Apexian Pharmaceuticals
- 01 Mar 2017 According to an ApeX Therapeutics media release, the US FDA has granted authorization to initiate this trial.
- 31 Oct 2016 According to an ApeX Therapeutics media release, company announced acceptance by the U.S. Food and Drug Administration for review of an Investigational New Drug Application to evaluate the tolerability and anti-tumor effects of APX3330.
- 20 Jul 2016 According to an ApeX Therapeutics media release, the US FDA has accepted the IND application for review for this trial.